# Genmab Publishes Managerial Share Transactions Under EU Market Abuse Regulation

> Genmab disclosed transactions in its shares by managerial employees and closely associated persons under Article 19 of the EU Market Abuse Regulation.

- Published: 2026-11-10T23:24:46+00:00
- Section: Business
- Author: News Desk
- URL: https://newsforagent.com/news/2026-11-10/genmab-managerial-share-transactions-disclosure
- Source: [GlobeNewswire](https://www.globenewswire.com/news-release/2026/11/10/3400372/0/en/transactions-with-shares-and-linked-securities-in-genmab-a-s-made-by-managerial-employees-and-their-closely-associated-persons.html)

## Key takeaways

- Genmab published a company announcement on November 10, 2026, disclosing transactions in its shares by managerial employees and their closely associated persons.
- The disclosure follows Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523.
- Genmab's managerial employees and their closely associated persons gave the company power of attorney to publish their trades.

Genmab A/S disclosed transactions in its shares made by managerial employees and their closely associated persons in a company announcement dated November 10, 2026. The Copenhagen-based biotechnology company published the disclosure through [GlobeNewswire](https://www.globenewswire.com/news-release/2026/11/10/3400372/0/en/transactions-with-shares-and-linked-securities-in-genmab-a-s-made-by-managerial-employees-and-their-closely-associated-persons.html).

## How the Genmab Disclosure Was Filed

[Genmab](https://akta.pro/company-profiles/00003bd/genmab) said the document sets out the data of transactions made in the company by managerial employees and their closely associated persons. The filing cites Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523.

Genmab said its managerial employees and their closely associated persons have given the company power of attorney on their behalf to publish trading in Genmab shares by those employees and persons. The announcement also includes forward-looking statements about the company's pipeline and risks.

Genmab is an international biotechnology company that develops antibody medicines for cancer and other serious diseases. It was established in 1999 and is headquartered in Copenhagen, with operations across North America, Europe and Asia Pacific. The company states that its science powers eight approved antibody medicines and that it is advancing a late-stage clinical pipeline that includes wholly owned programs.

## Genmab's Share Capital and Buy-Back Record

According to akta.pro [company records](https://akta.pro/company-data), Genmab completed a share capital reduction of DKK 1,900,000 through the cancellation of 1,900,000 shares, registered by the Danish Business Authority after approval at the company's Annual General Meeting on March 19, 2026. The same records show Genmab announced a share buy-back program starting February 18, 2026, to repurchase up to 342,130 shares with a maximum aggregate value of 725 million DKK by March 31, 2026, to honor commitments under its Restricted Stock Unit program.

## Genmab's Recent Filings Before the Disclosure

On November 10, 2026, Genmab said it would increase its share capital by 164,828 shares from employee warrant exercise, with no preemption rights, raising proceeds of approximately DKK 369.7 million, or about 0.2641% of its share capital, GlobeNewswire reported. On November 5, 2026, Investegate reported that Genmab posted adjusted operating profit of $1,108 million and adjusted operating expenses of $1,896 million for the first nine months of 2026. On November 4, 2026, Stock Titan reported that Genmab will present 22 epcoritamab abstracts at ASH 2026, including first results from the Phase 3 EPCORE DLBCL-4 study of epcoritamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma.

## Companies in this story

- [Genmab company profile](https://akta.pro/company-profiles/00003bd/genmab) · website: https://www.genmab.com

---
News for Agent · https://newsforagent.com/llms.txt